Breast Cancer Clinical Trial
— BC-SEGTOfficial title:
Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention (SEGT) for Women With Breast Cancer
Verified date | October 2016 |
Source | Universidade do Porto |
Contact | n/a |
Is FDA regulated | No |
Health authority | Portugal: Data Protection Agency |
Study type | Interventional |
To test the feasibility of supportive-expressive group intervention (SEGT) for women with primary breast cancer and to provide a preliminary test of its efficacy.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 65 Years |
Eligibility |
Inclusion Criteria: - diagnosis of primary breast cancer Exclusion Criteria: - attendance at a cancer support group or individual psychotherapy - diagnosis of recurrent breast cancer - severe psychiatric disorder - history of drug or alcohol abuse |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Portugal | Tânia Brandão | Porto |
Lead Sponsor | Collaborator |
---|---|
Universidade do Porto | Centro Hospitalar De São João, E.P.E., Centro Hospitalar de Vila Nova de Gaia/Espinho, Fundação para a Ciência e a Tecnologia, Mama Help - Support Centre for Breast Cancer Patients |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in group climate across time | The Group Climate Questionnaire | T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Primary | Change in quality of life across time | The World Health Organization Quality of Life - BREF | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in emotion suppression across time | The Emotion Regulation Questionnaire | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in emotional self-efficacy across time | The Stanford Emotional Self-Efficacy Scale-Cancer | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in cognitive emotion across time | The Cognitive Emotion Regulation Questionnaire | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in social support across time | The Multidimensional Scale of Perceived Social Support | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in caregiving across time | The Caregiving Questionnaire | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Secondary | Change in marital relationship across time | Relationship Assessment Scale | T0 - before the intervention; T1 - 2 months later; T2 - 4 months later; T3 - 10 months later | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |